• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

    2/14/24 4:00:26 PM ET
    $TCRR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TCRR alert in real time by email
    SC 13G/A 1 p26241sc13ga3.htm AMENDMENT NO. 3

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    TCR2 Therapeutics Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

     

    87808K106

    (CUSIP Number)

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐Rule 13d-1(b)

     

    ýRule 13d-1(c)

     

    ☐Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 
     

     

    CUSIP No. 87808K106

     

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

    12

    type of reporting person

     

    pN

     

     Page 2 of 8 
     

     

    CUSIP No. 87808K106

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL MANAGEMENT, LLC

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

    12

    type of reporting person

     

    oo

     

     Page 3 of 8 
     

     

    CUSIP No. 87808K106

     

    13G/A Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    KEVIN TANG

     

    2 Check the Appropriate Box if a Member of a Group*

    (a)  ¨

    (b)  ý

    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    UNITED STATES

    Number of

     Shares

     BENEFICIALLY
    Owned by

     Each Reporting
    Person with

    5

    Sole Voting Power

     

    0

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0%

    12

    type of reporting person

     

    IN

     

     Page 4 of 8 
     

     

    Item 1(a).Name of Issuer:

     

    TCR2 Therapeutics Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    100 Binney Street, Suite 710, Cambridge, MA 02142

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 87808K106

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 
     

     

    (b)Percent of Class:

     

    Tang Capital Partners 0%
    Tang Capital Management 0%
    Kevin Tang 0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date:  February 14, 2024    
           
           
    TANG CAPITAL PARTNERS, LP  
           
    By: Tang Capital Management, LLC, its General Partner  
           
           
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
           
           
    TANG CAPITAL MANAGEMENT, LLC  
           
           
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
           
           
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

    Get the next $TCRR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TCRR

    DatePrice TargetRatingAnalyst
    1/19/2022$28.00 → $5.00Buy → Neutral
    Goldman
    1/13/2022$25.00 → $19.00Buy
    HC Wainwright & Co.
    11/19/2021$55.00 → $26.00Overweight
    Piper Sandler
    11/10/2021$8.00 → $7.00Market Perform
    SVB Leerink
    10/21/2021$18.00 → $8.00Outperform → Mkt Perform
    SVB Leerink
    9/20/2021$40.00 → $29.00Buy
    Truist Securities
    9/20/2021$37.00 → $25.00Buy
    HC Wainwright & Co.
    9/17/2021$45.00 → $11.00Outperform → Neutral
    Wedbush
    More analyst ratings

    $TCRR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Tang Kevin C disposed of 4,394,800 shares (SEC Form 4)

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      2/14/24 5:25:51 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Ubs Oncology Impact Fund L.P.

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      6/5/23 4:37:26 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Mpm Sunstates Fund, L.P.

      4 - TCR2 THERAPEUTICS INC. (0001750019) (Issuer)

      6/5/23 4:36:51 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    SEC Filings

    See more
    • SEC Form 15-12G filed by TCR2 Therapeutics Inc.

      15-12G - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/12/23 7:00:31 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TCR2 Therapeutics Inc.

      EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/6/23 12:15:13 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by TCR2 Therapeutics Inc.

      EFFECT - TCR2 THERAPEUTICS INC. (0001750019) (Filer)

      6/6/23 12:15:11 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Financials

    Live finance-specific insights

    See more

    $TCRR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TCRR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $TCRR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

      Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapiesFollowing closing of the transaction, cash runway extended into 2026Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined companyCompanies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT)Philadelphia, Pennsylvania, Oxford, United Kingdom, and Cambridge, Massachusetts--(Newsfile Corp. - Ma

      3/6/23 6:00:00 AM ET
      $ADAP
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

      Compelling clinical data with clear paths to products and multiple near‐term value-creating catalysts Complementary technology platforms designed to treat solid tumors which represents a substantial market opportunity largely unaddressed by cell therapies Following closing of the transaction, cash runway extended into 2026 Following the all-stock transaction, currently expected to close in Q2 2023, Adaptimmune shareholders will own ~75% and TCR² Therapeutics stockholders will own ~25% of the combined company Companies to host a joint Webcast today, March 6, 2023, at 8:00 a.m. EST (1:00 p.m. GMT) PHILADELPHIA and OXFORD, U.K. and CAMBRIDGE, Mass., March 06, 2023 (GLOBE NEWSWIRE) -- Ada

      3/6/23 6:00:00 AM ET
      $ADAP
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma

      - Completed Phase 1 clinical trial establishes gavo-cel monotherapy as the first anti-mesothelin cell therapy to demonstrate tolerability and clinical benefit- Second RECIST partial response in ovarian cancer supports broad potential of gavo-cel- Consistent tumor regression in 28 of 30 (93%) evaluable patients with disease control rate of 77%- Progression-free survival of 5.6 months and overall survival of 11.2 months suggest durability of benefit in mesothelioma- Phase 2 portion of trial underway implementing multiple approaches to further improve clinical outcomes- TCR2 to host a conference call on Wednesday, September 28, 2022 at 8:00a.m. ET CAMBRIDGE, Mass., Sept. 28, 2022 (GLOBE NE

      9/28/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR2 Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded TCR2 Therapeutics from Buy to Neutral and set a new price target of $5.00 from $28.00 previously

      1/19/22 7:24:24 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on TCR2 Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of TCR2 Therapeutics with a rating of Buy and set a new price target of $19.00 from $25.00 previously

      1/13/22 6:21:23 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler resumed coverage on TCR2 Therapeutics with a new price target

      Piper Sandler resumed coverage of TCR2 Therapeutics with a rating of Overweight and set a new price target of $26.00 from $55.00 previously

      11/19/21 7:50:47 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

      CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR) (TCR2 or the Company), a clinical-stage cell therapy company with a pipeline of novel next-generation T cell therapies for patients suffering from solid tumors, today announced financial results for the first quarter ended March 31, 2023 and provided a corporate update. "We are pleased with our continued progress during the last quarter which included the announcement of the strategic combination of TCR2 with Adaptimmune. We believe that the integration of the two companies' complimentary technology platforms and pipelines focused on treating solid tumors has the potential to fundamentally change the w

      5/11/23 6:30:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 2,000 shares of TCR2's common stock to one non-executive new hire. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.77, which represents the closing market price

      5/8/23 4:05:00 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      CAMBRIDGE, Mass., April 03, 2023 (GLOBE NEWSWIRE) --  TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the Compensation Committee of the Board of Directors of TCR2 approved the grant of inducement stock options covering an aggregate of 6,000 shares of TCR2's common stock to two non-executive new hires. The stock options were granted as an inducement material to the employees' acceptance of employment with TCR2 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price per share equal to $1.50, which represents the closing mar

      4/3/23 4:15:00 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      2/14/24 4:00:26 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      5/5/23 4:37:07 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by TCR2 Therapeutics Inc. (Amendment)

      SC 13G/A - TCR2 THERAPEUTICS INC. (0001750019) (Subject)

      2/14/23 4:00:28 PM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $TCRR
    Leadership Updates

    Live Leadership Updates

    See more
    • TCR² Therapeutics Appoints Industry and Finance Veteran Eric Sullivan as Chief Financial Officer

      CAMBRIDGE, Mass., June 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Eric Sullivan as Chief Financial Officer where he will be responsible for leading all aspects of financial management and capital market strategy as well as overseeing investor relations and select business operations. "We are excited to announce Eric Sullivan is joining the TCR2 team as Chief Financial Officer," said Garry Menzel, Ph.D., President and Chief Executive Officer of TCR2 Therapeutics. "Eric brings a tremendous breadth of financial,

      6/27/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Announces Experienced Biotech Executive Rosemary Harrison as Chief Business and Strategy Officer

      CAMBRIDGE, Mass., Jan. 12, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the appointment of Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities. "We are pleased to welcome Dr. Rosemary Harrison as our first Chief Business and Strategy Officer at TCR2 as she has proven throughout her career an ability to work closely with multiple commercial function

      1/12/22 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of Directors

      CAMBRIDGE, Mass., Aug. 26, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced the appointment of Priti Hegde, Ph.D., to its Board of Directors. Dr. Hegde brings to TCR2 over 20 years of cancer genomics and immunology, clinical product development and early stage research experience in the biopharmaceutical industry, including an interdisciplinary focus on translational medicine. In connection with Dr. Hegde's arrival, Patrick Baeuerle, Ph.D., will be stepping down from the Board of Directors effective August 24, 2021 but will continue to serve TCR2

      8/26/21 6:45:00 AM ET
      $TCRR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care